This Week in Oncology — May 14, 2026

Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning major advances in treating central nervous system malignancies, new strategies for refining breast cancer therapy, and a look at emerging therapeutic platforms. Let's dive in.
This week's papers:
• Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy. — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42134381)
• MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial. — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42134380)
• Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges. — Cell 2026 (pubmed.ncbi.nlm.nih.gov/42134305)
• Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment. — Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42133905)
• Ecotypes of triple-negative breast cancer in response to chemotherapy. — Nature 2026 (pubmed.ncbi.nlm.nih.gov/42129561)
• Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery. — The New England journal of medicine 2026 (pubmed.ncbi.nlm.nih.gov/42127296)
• uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target. — Science translational medicine 2026 (pubmed.ncbi.nlm.nih.gov/42127223)
• Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts. — Science translational medicine 2026 (pubmed.ncbi.nlm.nih.gov/42127218)
• Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial. — Nature cancer 2026 (pubmed.ncbi.nlm.nih.gov/42120910)
• AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology. — Cell 2026 (pubmed.ncbi.nlm.nih.gov/42105763)
Listen at AudioScholar (audioscholar.cc/episode/a2ea5z6285)